The asymmetrical dimethylarginine (ADMA) - Multiple organ failure hypothesis

Clinical Nutrition

Volumn 22, Issue 1, 2003, Pages 99-104

  Nijveldt, R J ^a   Teerlink, T ^a   Van Leeuwen, P A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CRITICAL ILLNESS; DISEASE ASSOCIATION; HUMAN; HYPOTHESIS; INTENSIVE CARE UNIT; LIVER FUNCTION; LIVER METABOLISM; MORTALITY; MULTIPLE ORGAN FAILURE; RISK FACTOR;

EID: 12244283055     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1054/clnu.2002.0614     Document Type: Article

References (38)

1. Baue A E, Durham R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 1998; 10: 79-89
2. Harbrecht B G, Doyle H R, Clancy K D, Townsend R N, Billiar T R, Peitzman A B. The impact of liver dysfunction on outcome in patients with multiple injuries. Am Surg 2001; 67: 122-126
3. Harbrecht B G, Billiar T R, Stadler J, Demetris A J, Ochoa J B, Curran R D, Simmons R L. Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med 1992; 20: 1568-1574
4. Wright C E, Rees D D, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57
5. Nijveldt R J, Teerlink T, van der Hoven B, Siroen M P C, Kuik D J, Rauwerda J A, van Leeuwen P A M. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30
6. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-2097
7. + carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73
8. Tojo A, Welch W J, Bremer V et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601
9. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
10. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
11. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-548
12. Clarke S. Protein methylation. Curr Opin Cell Biol 1993; 5: 977-983
13. Davies K J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 2001; 83: 301-310
14. Ito A, Tsao P S, Adimoolam S, Kimoto M, Ogawa T, Cooke J P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095
15. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362
16. Fukatsu K, Saito H, Fukushima R, Inoue T, Lin M T, Inaba T, Muto T. Detrimental effects of a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine-methyl-ester) in a murine sepsis model. Arch Surg 1995; 130: 410-414
17. Murray-Rust J, Leiper J, McAlister M et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001; 8: 679-683
18. Nijveldt R J, Teerlink T, Siroen M P C, van Lambalgen A A, Rauwerda J A, van Leeuwen P A M. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003; 22: 17-22
19. White B J. Nitric oxide in the gastrointestinal system. In: Wallace JL (ed). Immunopharmacology of the Gastroinestinal Sytem. New York: Academic Press, 1993: 135-167
20. G-methylarginine requires NADPH-dependent hydroxylation. J Med Chem 1993; 36: 491-496
21. Worrall N K, Chang K, LeJeune W S, Misko T P, Sullivan P M, Ferguson Jr, T B, Williamson J R. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and - independent mechanisms. Am J Physiol 1997; 273: H2 565-H2 574.
22. Cerwinka W H, Cooper D, Krieglstein C F, Feelisch M, Granger D N. Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am J Physiol Heart Circ Physiol 2002; 282: H1111-H1117
23. Katusic Z S. Nitric oxide: regulator of P-selectin expression. Gastroenterology 1994; 107: 1199-1201
24. Lin H C, Wang C H, Yu C T, Hwang K S, Kuo H P. Endogenous nitric oxide inhibits neutrophil adherence to lung epithelial cells to modulate interleukin-8 release. Life Sci 2001; 69: 1333-1344
25. Böger R H, Bode-Böger S M, Tsao P S, Lin P S, Chan J R, Cooke J P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295
26. Doursout M F, Kilbourn R G, Hartley C J, Chelly J E. Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock model. J Crit Care 2000; 15: 22-29
27. Meyer J, Traber L D, Nelson S, Lentz C W, Nakazawa H, Herndon D N, Noda H, Traber D L. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992; 73: 324-328
28. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-1558
29. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-39
30. Avontuur J A, Bruining H A, Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 1995; 76: 418-425
31. Avontuur J A, Biewenga M, Buijk S L, Kanhai K J, Bruining H A. Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock 1998; 9: 451-454
32. Cohen R I, Hassell A M, Marzouk K, Marini C, Liu S F, Scharf S M. Renal effects of nitric oxide in endotoxemia. Am J Respir Crit Care Med 2001; 164: 1890-1895
33. Chu C J, Wang S S, Lee F Y et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur J Clin Invest 2001; 31: 156-163
34. Holden D P, Fickling S A, Whitley G S, Nussey S S. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998; 178: 551-556
35. Leiper J M, Santa M J, Chubb A, MacAllister R J, Charles I G, Whitley G S, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-214
36. Cadnapaphornchai M A, Ohara M, Morris Jr K G et al. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. Am J Physiol Renal Physiol 2001; 280: F592-F598.
37. Molnar M, Suto T, Toth T, Hertelendy F. Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol 1994; 170: 1458-1466
38. Yallampalli C, Garfield R E. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol 1993: 169: 1316-1320